Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials
Bea JW et al. - Despite early preservation of lean body mass with hormone therapy (HT) at 3 years, HT did not ameliorate long-term (6 years) loss in lean body mass with aging.
Participants were randomly divided into groups as follows : either estrogen plus progestogen therapy (n = 543) or control (n = 471) and estrogen therapy alone (n = 453) or control (n = 474).
They received dual-energy x-ray absorptiometry scans to estimate body composition during the Women's Health Initiative.
Falls and fracture occurrence were obtained by annual self-report.
Fractures were confirmed by a clinical chart review.
At 6 years post-randomization, lean body mass was not different between HT and control groups.
Although lean body mass positively influenced bone mineral density, independent of HT status, the preserved lean body mass observed in the HT arms in the first 3 years did not significantly contribute to models evaluating HT influence on falls and fractures between years 3 and 6.
Women taking at least 80% of their medication in the HT arms demonstrated fewer falls compared with placebo; this difference was not attributable to change in lean body mass.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.